Benitec Biopharma Limited Debt/Equity

Debt/Equity of BNTC for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.

Highlights and Quick Summary

  • Debt/Equity for the quarter ending March 31, 2023 was 0.13 (a 73.49% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -53.02%
  • Annual Debt/Equity for 2022 was 0.19 (a -31.06% decrease from previous year)
  • Annual Debt/Equity for 2022 was 0.28 (a Infinity% increase from previous year)
  • Annual Debt/Equity for 2021 was 0.0 (a -100.0% decrease from previous year)
Visit stockrow.com/BNTC for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Benitec Biopharma Limited

Most recent Debt/Equityof BNTC including historical data for past 10 years.

Interactive Chart of Debt/Equity of Benitec Biopharma Limited

Benitec Biopharma Limited Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2023 0.13 – – – –
2022 0.08 0.05 0.28 0.12 0.19
2021 0.08 0.06 0.01 0.02 0.0
2020 0.02 0.05 0.02 0.04 0.02
2019 – – – 0.02 0.0
2018 – – – – 0.0
2017 – – – 0.0 0.0
2016 – 0.0 0.0 0.0 0.0
2015 – – 0.0 0.0 0.0
2014 – – 0.0 0.0 0.0
2013 0.0 – – – 0.0

Business Profile of Benitec Biopharma Limited

Sector: Healthcare
Industry: Biotechnology
© stockrow.com